Since the drug’s launch, the company said more than 12,000 patients have received prescriptions for the medicine and it has been dispensed to 2,500 doctors.
Overall, the company reported second-quarter net income of $79.8 million, or 21 cents a share, compared with losses of $84 million, or 25 cents a share, in the year-ago period. The United Kingdom-based company’s net income benefited from a $104.1 million gain on the sale of one of its intangible assets. Revenue rose to $72 million from $3.3 million in the year-ago period. [Read more at MarketWatch]